leadf
logo-loader
viewVolitionRx

VolitionRx says veterinary oncology experts contribute to report ahead of Nu.Q Vet Cancer Screening Test launch

The panel reviewed data presented at the Veterinary Cancer Society Virtual Annual Conference in October, which demonstrated the successful use of the blood-based Nu.Q Vet Cancer Screening Test for dogs with lymphoma and hemangiosarcoma

pet
The report for veterinarians, entitled “A Look to the Future of Cancer Diagnostics,” explores the promise of molecular diagnostics in veterinary oncology, especially for hard to find tumors

VolitionRx Limited (NYSEAMERICAN:VNRX) announced a report Tuesday with contributions from four global leaders in veterinary oncology ahead of the expected launch of its first animal-test product -- the Nu.Q Vet Cancer Screening Test.

In a statement, the Belgian company said the comprehensive new report for veterinarians, entitled “A Look to the Future of Cancer Diagnostics,” explores the promise of molecular diagnostics in veterinary oncology, especially for hard to find tumors. 

Volition said the report, which is the outcome of a round table event hosted by subsidiary Volition Veterinary Diagnostics Development LLC, also introduced Volition's Nu.Q technology and Nu.Q Vet Cancer Screening Test. Dr Heather Wilson-Robles, professor of Oncology at Texas A&M University and chief medical officer at Volition Veterinary, was one of the panelists.

READ: VolitionRx on the path to launch first commercial products using Nu.Q platform as it ends 2Q with $21.3 million in cash

The panel reviewed data from results presented at the Veterinary Cancer Society Virtual Annual Conference in October, which demonstrated the successful use of the blood-based Nu.Q Vet Cancer Screening Test for dogs with lymphoma and hemangiosarcoma, a cancer of blood vessel walls, which together make up approximately one-third of canine cancers. They also discussed topics including the potential of early cancer diagnosis to help improve the treatment and quality of life, as well as supporting the clinical decision-making process.

"Volition's platform is very exciting,” said Dr Tim Fan, program leader, cancer discovery platforms, and professor of Veterinary Clinical Medicine at the Cancer Center at Illinois.

“Nucleosomes are very stable biomarkers that can be found in circulation and bringing this technology to the veterinary market is a very important first step. I look forward to seeing Volition adapt to the needs of the clients, pets and pet-owners that will benefit from this diagnostic test."

Dr Wilson-Robles added: “Cancer screening is not as commonplace in animal health as it is in human health, but blood tests like the Nu.Q Vet Cancer Screening Test could transform how we manage cancer in companion animals."

Cancer is the most common cause of death in dogs over the age of two years old in the US and up to 50% of all dogs over the age of 10 develop cancer in their lifetime. Together, Lymphoma and Hemangiosarcoma make up approximately one-third of canine cancers. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time-consuming, and/or painful for the animal. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: VolitionRx

Price: 4.08 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $215.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

on 11/13/2020

3 min read